当地时间12月7日，本次美国血液学会（ASH）大会备受关注的“ASH老年急性髓系白血病（AML）的临床实践指南更新”专场会议顺利召开。本次会议由指南牵头专家、西尔维斯特综合癌症中心血液科主任Mikkael ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

Ziftomenib是一种强效、选择性口服、在研的Menin抑制剂，目前正在开发用于治疗AML患者。2024 年 4 月，基于KOMET-001临床试验的数据，FDA授予Ziftomenib BTD（突破性治疗认定），用于治疗携带NPM1突变的R/R AML成人患者。2025 年 6 月 1 ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

Arog’s Phase III trial of crenolanib met its primary endpoint and improved OS and EFS in patients with NPM1/FLT3 co‑mutated ...

CLN-049’s anti-leukaemic impact was observed regardless of FLT3 status, which is the most commonly mutated protein in AML.

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML ...